Evaluation of the impact of meningococcal serogroup A conjugate vaccine on the childhood immunization program’s second-year-of-life vaccination coverage in Burkina Faso

Details

• Alternative Title:
  J Infect Dis
• Personal Author:
  Zoma, Robert L. ; Walldorf, Jenny A. ; Tarbangdo, Felix ; Patel, Jaymin C. ; Diallo, Alpha Oumar ; Nkwenkeu, Sylvain F. ; Kambou, Ludovic ; Nikiema, Moumouni ; Ouedraogo, Arnaud ; Bationo, Ange B. ; Ouili, Romeo ; Badolo, Hermann ; Sawadogo, Guetawende ; Akshaya, Krishnaswamy ; Hatcher, Cynthia ; Hyde, Terri B. ; Aké, Flavien ; Novak, Ryan T. ; Wannemuehler, Kathleen ; Mirza, Imran ; Medah, Isaïe ; Soeters, Heidi M.
• Description:
  Background:
  
  Following successful meningococcal serogroup A conjugate vaccine (MACV) campaigns since 2010, Burkina Faso introduced MACV in March 2017 into the routine Expanded Programme for Immunization (EPI) schedule at age 15–18 months, concomitantly with second-dose measles-containing vaccine (MCV2). We examined MCV2 coverage in pre- and post-MACV introduction cohorts to describe observed changes regionally and nationally.
  
  Methods:
  
  A nationwide household cluster survey of children 18–41 months of age was conducted 1 year after MACV introduction. Coverage was assessed by verification of vaccination cards or recall. Two age groups were included to compare MCV2 coverage pre-MACV introduction (30–41 months) versus post-MACV introduction (18–26 months).
  
  Results:
  
  In total, 15,925 households were surveyed; 7,796 children were enrolled, including 3,684 30–41 months of age and 3,091 18–26 months of age. Vaccination documentation was observed for 86% of children. MACV routine coverage was 58% (95% confidence interval [CI]:56–61%) with variation by region (41–76%). MCV2 coverage was 62% (CI:59–65%) pre-MACV introduction and 67% (CI:64–69%) post-MACV introduction, an increase of 4.5% (CI:1.3–7.7%). Among children who received routine MACV and MCV2, 93% (CI:91–94%) received both at the same visit. Lack of caregiver awareness about the 15- to 18-month visit and vaccine unavailability were common reported barriers to vaccination.
  
  Conclusion:
  
  A small yet significant increase in national MCV2 coverage was observed 1 year post-MACV introduction. MACV/MCV2 co-administration was common. Findings will help inform strategies to strengthen second-year-of-life immunization coverage, including to address the communication and vaccine availability barriers identified.
  
  
• Keywords:
  Adolescent Adult Burkina Faso Conjugate Meningococcal Vaccine Female Humans Immunization Programs Immunization Schedule Infant Male Mass Vaccination Measles Vaccine Meningitis, Meningococcal Meningococcal Vaccines Middle Aged Neisseria Meningitidis, Serogroup A Outcome Assessment, Health Care Serogroup A Meningococcal Meningitis Vaccination Coverage Vaccines, Conjugate Young Adult

  More +
• Source:
  J Infect Dis. 220(220 Suppl 4):S233-S243
• Pubmed ID:
  31671442
• Pubmed Central ID:
  PMC10718265
• Document Type:
  Journal Article
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Volume:
  220
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:120975c3115a00ed81dc8b30c9c54115af69beb9c1ae2baec78e6a1f528bbca4
• Download URL:
  https://stacks.cdc.gov/view/cdc/137346/cdc_137346_DS1.pdf
• File Type:
  [PDF - 289.89 KB ]